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DOI 10.1016/j.ccr.2010.10.031SUMMARYActivation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTORC1-
mediated inhibition of upstream signaling. We now show that AKT inhibition induces the expression and
phosphorylation of multiple receptor tyrosine kinases (RTKs). In a wide spectrum of tumor types, inhibition
of AKT induces a conserved set of RTKs, including HER3, IGF-1R, and insulin receptor. This is in part due
to mTORC1 inhibition and in part secondary to a FOXO-dependent activation of receptor expression.
PI3K-AKT inhibitors relieve this feedback and activate RTK signaling; this may attenuate their antitumor
activity. Consistent with this model, we find that, in tumors in which AKT suppresses HER3 expression,
combined inhibition of AKT and HER kinase activity is more effective than either alone.INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K)—protein kinase B
(PKB/AKT)—mammalian target of rapamycin complex 1
(mTORC1) kinase cascade transmits signals from ligand-stimu-
lated receptor tyrosine kinases (RTKs) to effector molecules
that control metabolism, proliferation, size, survival, and motility
(Guertin and Sabatini, 2007; Vivanco and Sawyers, 2002). In
cancer this pathway is frequently hyperactivated as a result of:
(1) activation of RTKs by mutation (epidermal growth factor
receptor) or gene amplification (HER2), (2) activating mutations
of components of the pathway such as PI3K or AKT, and (3) dele-
tion or decreased function of tumor suppressors such as the
PIP3 phosphatase, phosphatase and tensin homolog (PTEN)
(Hynes and Lane, 2005; Vivanco and Sawyers, 2002). Such
lesions are extremely common in cancer.
Tumorswith PTEN or PIK3CAmutations or HER2 amplification
have been shown to be dependent on PI3K-AKT-mTORSignificance
Constitutive feedback inhibition of upstream signaling pathway
teins. AKT activation leads to feedback by inhibiting the nucle
activating mTOR kinase. The antitumor effects of inhibitors o
tumors with activation of PI3K-AKT signaling, AKT inhibitors
FOXO and inhibiting mTORC1. In contrast, rapamycin inhibit
components of the activated pathway will relieve different as
combining signaling inhibitors with inhibitors of the specific p
58 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.signaling for maintenance of the transformed phenotype and
hypersensitive to inhibition of its components. This has led to
a major effort to develop inhibitors of PI3K, AKT, mTOR, and
other components of the pathway (Courtney et al., 2010;
Workman et al., 2010). Analogs of the natural product rapamy-
cin, an inhibitor of the mTORC1 complex, were among the first
inhibitors of the PI3K pathway to be used for the treatment of
cancer. Rapamycin does effectively inhibit mTORC1 signaling;
however, it also relieves mTORC1-dependent feedback inhibi-
tion of IGF1 receptor (IGF-1R) signaling. This results in activation
of PI3K-AKT signaling and enhanced phosphorylation of non-
mTORC1 targets of AKT, such as the FOXO family of transcrip-
tion factors (Haruta et al., 2000; O’Reilly et al., 2006).
Physiologic activation of signaling is regulated by feedback
inhibition of components of the network and is a feature of
both normal and oncogene-transformed cells. Relief of this feed-
back might be a common response to anticancer drugs and
could attenuate the therapeutic response (Courtois-Cox et al.,s is a fundamental feature of tumors with activated oncopro-
ar localization of FOXO and other transcription factors and
f oncoproteins may be attenuated by relief of feedback. In
activate receptor signaling and expression by activating
s mTORC1 but activates AKT. Thus, inhibitors of different
pects of negative feedback. Effective therapy may require
athways they induce.
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AKT Inhibition Induces RTK Expression2006; O’Reilly et al., 2006). We reasoned that specific inhibitors
of other components of the PI3K-AKT pathway would reactivate
different aspects of the network. To examine the role played by
AKT in the feedback regulation of activated mitogenic signal
transduction, we employed a specific, allosteric AKT inhibitor
and examined its effect on the expression and phosphorylation
of the RTKs that commonly stimulate these signaling pathways
(DeFeo-Jones et al., 2005; Lindsley et al., 2005; She et al., 2008).
RESULTS
AKT Inhibition Is Associated with HER3 Induction
We used selective inhibitors to determine whether AKTmediates
feedback inhibition of PI3K signaling in tumors in which it is dys-
regulated. AKTi-1/2 and AKTi-1/2/3 are PH-domain dependent,
non-ATP-competitive inhibitors that potently inhibit AKT1 and
AKT2, and not other AGC kinases, with AKTi-1/2/3 having
greater potency against AKT3 (Barnett et al., 2005; Lindsley
et al., 2005). The drugs share similar potency against activated
AKT in the HER2-amplified breast cancer cell line BT-474, as
seen in Figure S1 (available online) (She et al., 2008). The drugs
prevent binding of AKT to the plasma membrane and, thus, its
phosphorylation by PDK1, so, unlike ATP-competitive inhibitors,
they block rather than activate AKT phosphorylation (Figure 1A)
(Okuzumi et al., 2009).
Breast cancers with HER2 amplification have elevated levels
of AKT and ERK phosphorylation and are dependent on the
former, but not the latter for maintenance of the transformed
phenotype (Basso et al., 2002; Hermanto et al., 2001; She
et al., 2008; Solit et al., 2006). In these tumors, PI3K-AKT
signaling is HER2 dependent and predominantly driven by
HER2-HER3 heterodimers (Holbro et al., 2003; Yakes et al.,
2002). HER3 is a kinase-defective member of the HER kinase
family that contains six tyrosines in its intracellular domain that,
when phosphorylated, act as high-affinity docking sites for the
p85 subunit of PI3K. In breast cancers, overexpressed HER2
dimerizes with and phosphorylates HER3, which binds to and
activates PI3K (Holbro et al., 2003).
AKT inhibitors block AKT signaling in these cells and cause
growth arrest and apoptosis (She et al., 2008). We asked
whether activation of AKT feedback regulates the HER kinase
family members that drive the pathway. In Figure 1A we deter-
mined the effect of AKT inhibition on HER kinase expression
and phosphorylation in BT474, a breast cancer cell line with
HER2 amplification. Treatment of BT-474 cells with 1 mM AKTi-
1/2 inhibits phosphorylation of AKT and its substrate, PRAS40,
by 1 hr after drug is added. At 24 hr, AKT phosphorylation begins
to rise but remains significantly inhibited at 72 hr. AKT inhibition
causes a marked change in the expression and phosphorylation
of HER kinase family members. The expression of EGFR, HER3,
and HER4 is induced beginning 2–4 hr after drug addition and
reaches a maximum approximately 24 hr after drug exposure
(1.6-, 4.1-, and 2.5-fold induction). The already high levels of
HER2 expression do not change appreciably. There is a concom-
itant 4-fold induction of the tyrosine phosphorylation of HER3 at
both the Y1197 and Y1289 sites, whereas phosphorylation of
EGFR (Y1068), HER2 (Y1221), and HER4 (Y1284) declines over
this period (0.4-, 0.5-, and 0.7-fold). Of the HER family receptors,
only HER3 expression and phosphorylation are coordinately up-regulated in these cells. Inhibition of the PI3K-AKT pathway
using an ATP competitive AKT kinase inhibitor or a PI3K inhibitor
also results in upregulation of HER3 and P-HER3 expression
(Figure S1). Moreover, interfering RNA against AKT1, AKT2,
and AKT3 results in induction of HER3 expression and phos-
phorylation 72 hr after transfection (Figure 1B). HER3 levels in
the plasma membrane increase, and this is accompanied by
increased HER3 heterodimerization with HER2 and association
with the p85 subunit of PI3K (Figure S1). These data suggest
that PI3K-AKT activation in response to HER2 amplification
and overexpression is associated with an AKT-dependent
downregulation of HER family protein expression, which is
relieved by the AKT inhibitor. Although AKT and ERK signaling
are both driven by HER2 amplification, feedback regulation of
receptor expression is mediated by the former, but not the latter.
Selective inhibition of ERK phosphorylation with the MEK inhib-
itor, PD325901, has no effect on HER2 or HER3 expression or
phosphorylation in tumor cells with HER2 amplification
(Figure 1C).
Induction of HER3 expression in response to AKT inhibition
does not require serum factors. Serum starvation of HER2-
amplified breast cancer cells is associated with increased
HER3 expression, and increased phosphorylation of HER2,
HER3, and AKT (Figure 1D). In these cells, 1 mM AKTi-1/2 led
tomarked induction of HER3 expression, but no further induction
of HER3 phosphorylation. The results distinguish induction of
phosphorylation of the receptor from induction of expression.
Whereas AKT inhibition can further induce HER3 expression in
the absence of serum factors, it does not affect HER3
phosphorylation.
Induction of AKT Activation Reduces HER3 Expression
These results suggest that in HER2-amplified breast cancer
cells, PI3K activation may induce an AKT-dependent feedback
inhibition of HER3 expression and activation. To assess the
effects of inducing AKT activation, BT-474 cells were treated
with DMSO or 100 nM AKTi-1/2/3 in serum containing media
for 12 hr (lanes 2 and 7, Figure 2A) and then the compound
was washed out, and fresh medium was added (Figure 2A). Re-
activation of AKT phosphorylation occurred 4 hr after the drug
was removed and was sustained. This was associated with
decreased HER3 expression and phosphorylation 8 hr after
drug washout. Levels of HER3 and phosphorylated HER3
declined to near steady-state levels. The data suggest that
AKT activation negatively regulates HER3 expression and
phosphorylation in HER2-amplified breast cancer cells and
that inhibition of AKT relieves this feedback.
The Phosphorylation of Multiple RTKs Is Induced
by AKT Inhibition
Multiple RTKs activate PI3K-AKT signaling in normal and tumor
cells. In particular, many of the metabolic effects and other
consequences of stimulation of the insulin and IGF-1Rs are
mediated via induction of PI3K-AKT signaling. We used an
anti-phosphotyrosine receptor antibody array to assess whether
RTKs other than HER3 were induced in response to AKT inhibi-
tion (Figure 2B). These RTK arrays detect phosphorylation of 42
RTKs (Stommel et al., 2007). In BT-474 cells, HER2 and HER3
were the most prominent phosphorylated RTKs detectedCancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc. 59
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Figure 1. AKT Inhibition Promotes HER3 Expression and Phosphorylation
(A) BT474 cells were treated with AKTi-1/2 (1 mM) and collected at indicated times. AKT inhibition as measured by loss of S473 phosphorylation, along with AKT
targets S6K and PRAS40, is associated with increases in HER3 and P-HER3.
(B) BT-474 cells treated with siRNAs against AKT1, AKT2, and AKT3 (AKT3 was not detectable) for 72 hr were collected and lysates immunoblotted,
demonstrating that loss of AKT expression is associated with increased expression of RTKs.
(C) The HER2-amplified cancer cell lines BT-474 and SK-BR3 were treated with the MEK inhibitor PD325901 (50 nM). Inhibition of ERK1/2 phosphorylation was
not associated with an induction of HER3 or P-HER3.
(D) BT-474 and SK-BR3 cell lines were serum starved for 12 hr followed by treatment with 1 mM AKTi. The induction of HER3 expression occurred upon AKT
inhibition despite the lack of serum. See also Figure S1.
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AKT Inhibition Induces RTK Expression(first set of panels, 50 mg loaded). Twenty-four hours after expo-
sure to the AKT inhibitor, P-HER2 was not significantly changed,
whereas P-HER3 was strongly induced. Removing the anti-P-
HER2 and anti-P-HER3 dots from the array and increasing the
amount of loaded protein (250 mg) increased the sensitivity of
the assay. This allowed detection of multiple other receptors in
the untreated control. The phosphorylation of a group of RTKs
(HER3, FLT-3, HER4, EphA7, MSPR, insulin receptor [IR],60 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.EphA1, IGF-1R, FGFR3, and FGFR1) was induced at least
3-fold 24 hr after inhibition of AKT. The induction of the total
tyrosine phosphorylation of HER4, in which 19 P-TYR sites
have been identified, contrasts with the loss of phosphorylation
of the Y1284 site on HER4 in Figure 1A (Kaushansky et al., 2008).
Overall, the data suggest that the phosphorylation of a group of
receptors is feedback inhibited in response to PI3K-AKT activa-
tion and induced when AKT is inhibited.
P-AKT(S473)
HER 3
p85-PI3K
Time (hrs)
Untx -> washout    AKTi -> washout
BT-474
P-HER3 (Y1289)
-12   0     4    8   24  48   0     4    8   24  48  
A
B 1 3 5 7 9 13 15 17 19 21 2311
A
B
C
D
E
F
P-HER3
0 hr
A
B
C
D
E
F 24hr AKTi
BT-474(light exposure)
P-INSR, P-IGF-1R
BT-474(dark exposure)
0 hr
24hr AKTi
1 3 5 7 9 13 15 17 19 21 2311
A
B
C
D
E
F
A
B
C
D
E
F
Figure 2. Activation of AKT Represses HER3, Whereas Inhibition
Induces Several Phosphorylated RTKs
(A) BT-474 cells (at time = 12) were treated with AKTi-1/2/3 (100 nM) or
DMSO for 12 hr (until t = 0). Cells were then washed four times with PBS,
placed in fresh media, and collected at indicated times after (t = 4, 8, 24,
and 48 hr). Immunoblots demonstrate that loss of HER3 and P-HER3 corre-
lated with activation of AKT.
(B) BT474 cells were left untreated (0 hr) or treated with AKTi-1/2/3 (1 mM) for
24 hr and lysates applied to Phospho-RTK arrays. Spots are in duplicate, and
each pair corresponds to a specific P-RTK. Top set of blots correspond to
50 mg lysates, whereas bottom two correspond to 250 mg lysates with HER2
andHER3 dot blots excised from themembrane. Phospho-HER3 corresponds
to the doublet at B5 and shows increased expression with prolonged
treatment with the AKT inhibitor.
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AKT Inhibition Induces RTK ExpressionActivated RTKs Are Induced in Many Tumor Models
In HER2-amplified tumor cells, overexpression of HER2 dysre-
gulates PI3K-AKT signaling by promoting HER2-HER3 hetero-
dimer formation. Our data suggest that AKT activation feedback
downregulates HER3 and a set of other RTKs in these cells. We
askedwhether this is a general phenomenon or peculiar to tumor
cells in which HER2 drives PI3K-AKT signaling. We used the
phospho-RTK arrays to determine if the effects of AKT inhibition
on receptor phosphorylation were shared among different
cancer models (Figure 3A; Figure S2). Two additional HER2-
amplified cell lines (SK-BR3 and MDA-MB-453) were evaluated.
When the results were quantified and the mean of the 3 cell lines
taken, 12 receptors (HER3, IGF-1R, IR, HER2, HER4, MSPR,
SCFR, EphA1, EphA7, FLT-3, ROR1, and RET) had an induction
greater than 3-fold after 24 hr of AKT inhibition. P-HER3 was
highly induced in all three of these models. These results were
compared with six tumor cell lines lacking HER2 amplification
and representing four different cell lineages (LNCAP, prostate;
IGROV-1, ovarian; MDA-MB-231, breast; and NCI-H292,
NCI-H3255, and NCI-H1975, lung). In these six cell lines, nine
receptors had average inductions above 3-fold (HER3, IGF-1R,
IR, MER, MET, RET, ROR1, TIE-2, and EphA7). Comparing the
HER2 and non-HER2 lists, we noted overlap of IGF-1R, IR,
HER3, EphA7, and RET, which were significantly induced
(>3-fold mean induction) in the majority of these cell lines. We
evaluated the effect of AKT inhibition in a non-transformed,
breast epithelial cell line, MCF10A, and found that only IGF-1R,
IR, and PDGFRa were induced after AKT inhibition. Figure 3B
lists the receptors in the ten cell lines for which average phos-
phorylation was induced at least 3-fold. The number of cell lines
in which each receptor was induced and the average degree of
induction are shown. IGF-1R, IR, HER3, EphA7, and RET were
induced in the majority of models, whereas HER4, EphA1,
ROR1, and MET phosphorylations were induced in a subset.
We conclude that inhibition of AKT induces the phosphorylation
of a group of RTKs, and induction is not confined to a particular
type of tumor or to tumors in which signaling is driven by HER2.
AKT Inhibition Induces the Expression of the HER3,
IGF1R, and IRs
In BT-474 cells, AKT inhibition caused a parallel and equivalent
induction of HER3 phosphorylation and expression, consistent
with the possibility that the former is due to the latter. We
evaluated whether induction of HER3, IR, and IGF-1R phos-
phorylation could be explained by induction in the expression
of theseproteins. In sixout of sevencell lineswithoutHER2ampli-
fication, AKT inhibition caused increased levels of HER3 protein
(Figure 3C). Increases in IR were detected in five out of seven of
these cell lines, and IGF-1R was detected and induced in six
out of seven cell lines. In contrast, RET protein was detected
and induced in only two out of the seven cell lines, and HER4
protein was not induced in any of the seven (Figure 3C). The
induction in HER3, IGF-1R, and IR protein occurred in the
majority of tested models and was not restricted to a specific
tumor lineage. Moreover, in the non-transformed model,
MCF10A, upregulation in the protein levels of HER3, IR, and
IGF-1R was also observed. It was notable that induction of
phosphorylated IGF-1R and IR, but not P-HER3, was seen in
this model, which may be related to the comparably low levelsCancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc. 61
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Figure 3. RTKs Expression and Phosphorylation Are Induced by AKT Inhibition in Multiple Tumor Types
(A) Shown are immunoblots from representative Phospho-RTK arrays from cancer cell lines treated with 1 mM AKTi-1/2/3 (24 hr) compared to untreated (0 hr),
demonstrating that phosphorylation of several receptors is induced with inhibitor treatment. The HER2 and HER3 dot blots were excised from the membrane in
the case of SKBR-3 cell line shown here. See Supplemental Experimental Procedures for list of receptors corresponding to labels (e.g., B5 = HER3) and Figure S2
for other cell lines tested.
(B) Listed are the receptors in which average tyrosine phosphorylation (ten cell lines) induced >2.9-fold after 1 mM AKTi-1/2/3 (24 hr), as measured by densitom-
etry on P-RTK arrays. Mean induction and the number of cell lines with an induction (>1.3) are listed (cell lines: BT-474, H292, MCF10A, SKBR3, MDA231,
MDA453, LNCAP, H3255, H1975, IGROV1).
(C) A panel of seven non-HER2 amplified cell lines was treated with 1 mMAKTi-1/2/3, and immunoblots demonstrate induction of the expression of several RTKs.
(D) Listed is the fold induction of protein expression of HER3, IR, and IGF-1R after AKT inhibition calculated by densitometry from immunoblots. See also Table S1.
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AKT Inhibition Induces RTK Expressionof activated HER kinases in this cell. The average induction in
protein level of these three receptors across these cell lines and
additional HER2-amplified or EGFR mutant cancer cells was62 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.quantified by densitometry. All three receptors are commonly
induced (HER3, 13/14; IGF-1R, 12/14; IR, 14/14), with average
inductions of HER3 2.8-fold, IGF-1R 2.2-fold, and IR 2.5-fold.
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AKT Inhibition Induces RTK ExpressionInduction of expression of HER3, IGF1R, or IR was almost
always associated with increased phosphorylation (in 25 out of
28 instances). However, in most cases, induction of phosphory-
lationwas out of proportion to induction of expression (Table S1).
Therefore, the induction of phosphorylation of these proteins can
only be partially explained by increased protein expression.
Nevertheless, the data suggest that the expression of a common
set of receptors is upregulated among cell lines, and this corre-
lates with the induction of their phosphorylation in response to
AKT inhibition.
HER-Kinase Dependence of Induced P-RTKs
In most of the tumor cells we examined, the induction of HER3
phosphorylation was themost prominent effect of AKT inhibition.
We used selective HER1/2 kinase inhibitors to determine
whether induction of phosphorylation of receptors was HER-
kinase dependent. Lapatinib, a HER2/EGFR inhibitor that
potently blocks HER2 kinase, was used to address this question
in breast cancer cells with HER2 amplification (Karaman et al.,
2008). Gefitinib, which preferentially inhibits EGFR kinase
activity, was used in H292, a non-small cell lung cancer cell
line with overexpression of wild-type EGFR. We compared the
effects of the AKTi-1/2/3, lapatinib, or the combination on the
induction of receptor phosphorylation in the HER2-amplified
breast cancer cell (BT-474) (Figure 4A). After 24 hr exposure to
AKTi-1/2/3 (1 mM, second panel), phosphorylation of HER3,
IGF-1R, IR, and several other receptors was induced. When
the HER1/2 kinase inhibitor (1 mM) was combined with the AKT
inhibitor, levels of phosphorylated HER3, IGF-1R, and IR were
repressed below basal levels. Treatment with lapatinib alone
blocked the phosphorylation of all the assessed RTKs below
steady-state levels. The effect of the HER kinase inhibitors is
unlikely to be due to direct inhibition of IGF1R or IR kinases, to
which they do not bind avidly (Karaman et al., 2008). Moreover,
these inhibitors do not suppress IGF1R or IR phosphorylation in
H1975, in which the T790M mutant EGFR is resistant to gefitinib
(Figure S3). These data suggest that induction of IGF1R and
IR phosphorylation is HER2 dependent in breast cancers in
which this receptor is amplified.
We evaluated the HER-kinase dependence of induction of
receptor phosphorylation in a non-HER2-dependent model,
NCI-H292, as well. AKT inhibition resulted in induction of
phosphorylated HER3, IGF-1R, IR, and several other receptors,
including FGFR1 and EphA7 (Figures 4B; Figure S3). In this case
the AKTi induction of phosphorylation of some but not all of the
RTKs could be suppressed by the HER1/2 inhibitor gefitinib
(5 mM). For instance, phosphorylation of HER3 and IR is
suppressed below basal levels by the combination, and induc-
tion of P-EphA7 is significantly weaker. In contrast, induction
of P-FGFR1 is unaffected by gefitinib, and IGF-1R phosphoryla-
tion is supra-induced by the combination. The data suggest that
in cells in which HER2 is not the dominant RTK, the HER-kinase
dependence of induction of receptor phosphorylation is variable.
Induction of Receptor Expression by AKT Inhibitors
Is Not Dependent on HER Kinase Activity
AKT inhibition leads to a parallel induction of the expression and
phosphorylation of IGF-1R, IR, and HER3.We askedwhether the
induction of expression of these RTKs is dependent upon HERkinase activity as well. BT-474 cells were treated for 8 or 24 hr
with 1 mM AKTi-1/2/3, 1 mM lapatinib, or the combination (Fig-
ure 4C). As expected, both inhibitors block AKT phosphorylation
(P-S473). The induction of HER3 and IGF-1R/IR phosphorylation
(antibody detects both receptors) by the AKTi was completely
blocked by lapatinib. In contrast the induction of IGF-1R, IR,
and HER3 protein expression was unaffected by the addition
of lapatinib. Similarly, the AKTi-mediated induction of HER3
phosphorylation but not protein expression was blocked by
lapatinib in the H292 lung cancer cell line (Figure 4D). These
data show that the upregulation of receptor expression caused
by AKT inhibition is not dependent on HER kinase activity,
whereas the induction of phosphorylation is.
Inhibition of AKT but Not mTORC1 Induces HER3,
IGF-1R, and IR Expression
ThemTORC1 complex is one of the primary downstream targets
of AKT signaling. Direct inhibition of mTORC1 with rapamycin
blocks S6Kinase-dependent feedback inhibition of IRS-1 ex-
pression and activates IGF-1R signaling (O’Reilly et al., 2006).
We asked whether induction of receptor expression in response
to AKT inhibition was mediated by mTORC1 inhibition. The
effects of HER2, AKT, and mTORC1 inhibition on HER kinase
expression and signaling were examined in BT474 cells (Fig-
ure 5A). Cells were exposed to AKTi-1/2, lapatinib, or rapamycin
for up to 24 hr. Each inhibitor causes potent inhibition of its
respective target (P-HER2 for lapatinib, P-S6K for rapamycin,
and P-AKT for AKTi-1/2) at 8 and 24 hr. Rapamycin and
AKTi-1/2 each induces HER3 phosphorylation, although the
effect of the latter is moremarked (Figures 5A and 5B; Figure S4).
Both AKTi-1/2 and lapatinib inhibit AKT phosphorylation and
induce HER3 expression. In contrast, rapamycin does not
induce expression, only phosphorylation. Thus, AKT and
mTORC1 both regulate the feedback inactivation of HER kinase
signaling. However, mTORC1 affects HER3 phosphorylation, but
not expression. AKT, but not mTORC1, is responsible for the
feedback regulation of HER3 expression.
We compared the effects of rapamycin and AKTi-1/2 on the
phosphorylation of RTKs in BT474 (Figure 5B). After 24 hr of
treatment, the effects of the two drugs were markedly different.
Rapamycin induced HER3 phosphorylation more than 4-fold
(2.5-fold less than the AKTi-1/2) and had no effect on IR or
IGF1-R phosphorylation. Several other receptors (FLT-3,
HER4, MSPR, EphA1, and EphA7) whose phosphorylation was
induced by AKT inhibition were either less affected or unaffected
by rapamycin. In contrast, rapamycin induced the phosphoryla-
tion of two receptors (MER and MuSK) more potently than AKT
inhibition did. These findings suggest that inhibition of AKT and
mTORC1 relieves different aspects of PI3K-induced feedback.
AKT Inhibition Upregulates RTK Transcript Levels
Because levels of HER3, IGF-1R, and IR protein increase after
AKT inhibition, we determined whether the mRNAs encoding
these receptors were affected as well. We compared the effects
of AKT inhibition and mTORC1 inhibition on HER2, HER3,
IGF-1R, IR, RET, and MET mRNA levels. IR, HER3, and IGF-1R
mRNA levels were all induced between 2.5- and 5-fold after
exposure of cells to either the AKT inhibitor or lapatinib,, but
not to rapamycin (Figure 6A). Rapamycin induced only minorCancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc. 63
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Figure 4. HER Kinase Inhibition Does Not Block AKTi-Stimulated RTK Expression but Can Alleviate AKTi Induction of P-RTKs
(A) BT-474 cells were treated with DMSO, 1 mM AKTi-1/2/3, 1 mM lapatinib, or the combination. Immunoblots of P-RTK arrays were quantified by densitometry.
The effect of the HER1/2 kinase inhibitor upon the induction caused by AKT inhibition is shown with the induced expression of most P-RTKs blocked in the
combination treatment.
(B) NCI-H292 cells were treated with DMSO, 1 mMAKTi-1/2/3, 5 mMgefitinib, or the combination. The effect of the HER kinase inhibitor upon the induction caused
by the AKTi is shown with the induced expression of some P-RTKs blocked in the combination treatment.
(C) BT-474 cells were treated with DMSO, 1 mM AKTi-1/2/3, 1 mM lapatinib, or the combination and collected at 8 and 24 hr posttreatment. Immunoblotting
of lysates demonstrates AKTi or lapatinib, or the combination induces HER3, IGF-1R, and IR expression, but phosphorylation of these receptors is blocked
by lapatinib treatment.
(D) NCI-H292 cells were treated with 1 mM lapatinib, 1 mM AKTi-1/2/3, or the combination and collected at 4, 8, or 24 hr posttreatment, and lysates were immu-
noblotted showing induction of HER3 and P-HER3 in response to AKT inhibition and blockade of HER3 phosphorylation by lapatinib. See also Figure S3.
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AKT Inhibition Induces RTK Expressionchanges in mRNA expression. Expression of HER2, RET, and
METmRNAswas not induced by any of the inhibitors. The results
confirm that relief of feedback inhibition of RTK signaling in
response to AKT inhibition cannot be explained by inhibition of
mTORC1 alone. Feedback inhibition of mitogenic signaling in
response to AKT activation must be mediated by other targets
as well.64 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.FOXO Transcription Factors Mediate Induction
of RTK Expression
FOXO transcription factors regulate a number of genes involved
in cell survival and longevity and are inhibited when phosphory-
lated by AKT (Kenyon et al., 1993; Kops et al., 1999; Myatt and
Lam, 2007). The Drosophila IR has been demonstrated to be
dependent upon the activity of the FOXO transcription factor
AB
Fold inducon P-RTK in BT-474
1     3      5      7       9     11     13    15   17    19     21   23
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F
P-INSR, P-IGF-1R
AKTi
P-AKT (S473)
p85-PI3K
Time (hr)       0        8     24               0      8      24                 0       8      24
HER 3
P-HER3
P-HER 2 (Y1221)
AKT
P-S6K
HER2
Rapamycin Lapanib
P-RTK AKTi Rapa
HER3 12.1 4.6
HER4 3.2 1.0
INSR 2.4 0.5
IGF-IR 2.3 0.6
FLT-3 6.1 1.2
MSPR 2.9 1.5
Mer 1.7 2.0
Eph A1 2.4 0.7
Eph A7 3.1 0.5
MuSK 1.3 2.0
MET 0.2 1.0
AKTi
Rapamycin
Untreated
Figure 5. Inhibition of AKT but Not mTORC1
Promotes the Expression and Phosphoryla-
tion of Several RTKs
(A) BT-474 cells were treated with 1 mM AKTi-1/2,
50 nM rapamycin, or 500 nM lapatinib and
collected at indicated times. Loss of AKT S473
phosphorylation is associated with an induction
in HER3 protein levels, whereas treatment with
rapamycin is not associated with significantly
increased levels of HER3.
(B) BT474 cells were treated with 1 mMAKTi-1/2 or
50 nM rapamycin and lysates applied to Phospho-
RTK arrays. The HER2 and HER3 dot blots
were excised from the membranes shown here.
Densitometry was performed to calculate fold
induction over untreated cells. All receptors
induced >1.9-fold are listed. See also Figure S4.
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Because inhibition of the PI3K-AKT pathway causes dephos-
phorylation of FOXO proteins and prevents their nuclear translo-
cation, we investigated whether mammalian FOXO transcription
factors may be involved in the induction of the RTKs by the AKT
inhibitor (Myatt and Lam, 2007). FOXO1, 3, and 4 were depleted
individually and in combination using specific, small-interfering
RNAs, and the effect on basal and induced levels of receptors
was examined (Figure 6B). In BT-474 cells, knockdown of these
factors alone or in combination had little effect on steady-state
levels of HER3, IGF-1R, or IR mRNA expression. However, the
induction of receptor mRNA by the AKT inhibitor was markedly
diminished by FOXO knockdown. Of the three isoforms, inhibi-
tion of FOXO3 expression had the most potent effect, diminish-Cancer Cell 19, 58–7ing HER3, IGF1R, and IR induction by
64%, 90%, and 69%. Knocking down
FOXO1 or FOXO4 had less effect, dimin-
ishing HER3 and IR inductions by <20%.
However, combined knockdown of all
three isoforms was most potent, dimin-
ishing HER3, IGF1R, and IR induction by
73%, 91%, and 80% of that in the control
cells. Knockdown of FOXO isoforms had
comparable effects on receptor protein
expression in BT-474 cells and the non-
transformed MCF10A cell line (Figure 6D;
Figure S5). Moreover, the induction of
phosphorylation of HER3, IGF-1R, and
IR was significantly reduced in cells in
which FOXOs were silenced (Figure S5).
Induction of P-HER3 was reduced nearly
3-fold, whereas inductions of P-IGF-1R
and P-IR did not occur. The incomplete
suppression of induction of HER3 phos-
phorylation in cells in which FOXO
expression was knocked down is consis-
tent with the modest induction of HER3
phosphorylation by rapamycin (Figure 5).
This suggests that the increase in RTK
phosphorylation in response to AKT inhi-
bition is due both to a FOXO-dependentincrease in receptor expression and to increased phosphoryla-
tion in response to TORC1 inhibition. These data show that
activation of FOXOs in response to AKT inhibition is required
for the upregulation of RTK expression.
FOXO protein binding to the HER3, IGF-1R, and IR promoters
and whether binding is altered in response to AKT inhibition were
examined by chromatin immunoprecipitation (ChIP) assays
(Figure 6C). BT-474 cells were treated with AKT inhibitor, fixed
with formalin, and the total chromatin was collected. Immuno-
precipitation with a combination of antibodies against FOXO1,
FOXO3, and FOXO4 resulted in enhanced amplification of the
RTK 50UTR over input chromatin as measured by RT-PCR.
Exposure of cells to the AKT inhibitor resulted in an enhancement
of RTK amplification (HER3, 4.3-fold; IGF-1R, 2.4-fold, INSR,1, January 18, 2011 ª2011 Elsevier Inc. 65
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Figure 6. AKT but Not mTORC1 Inhibition Induces RTK RNA Expression in a FOXO-Dependent Manner
(A) BT-474 cells treated with 1 mM AKTi-1/2, 50 nM rapamycin, or 500 nM lapatinib, and RT-PCR was performed using reverse-transcribed cellular RNA. Fluo-
rescencewas normalized to housekeeping gene expression (b-actin andGAPDH) and is displayed as the percentage of the value for untreated lysate. Expression
of HER3, IGF-IR, and IR was induced by effective suppression of activated AKT but minimally with rapamycin treatment.
(B) BT-474 cells were treated with interfering RNAs against FOXO1 (siF1), FOXO3 (siF3), FOXO4 (siF4), FOXO1 + 3 + 4 (siFall), or mock (M) with or without AKTi-1/
2/3 (1 mM). Cells were collected 72 hr after siRNA transfection (24 hr after AKTi), and RT-PCR was performed with the indicated probes. Inhibition of AKT is asso-
ciated with enhanced expression of the HER3, IR, and IGF-1R RNAs. RNA induction is suppressed by FOXO1/3/4 knockdown.
(C) BT-474 cells were treated with FOXO1/3/4 siRNAs or mock for 48 hr followed by treatment with AKTi-1/2/3 (1 mM) or DMSO for 24 hr followed by formalin
fixation and isolation of chromatin. Immunoprecipitation was performed using antibodies against FOXO 1, 3, and 4, and RT-PCR was done with oligonucleotides
complementary to a sequence 1 kb 50 to the HER3, INSR, and IGF-1R start sites. Expression was normalized to the non-immunoprecipitated (input) fraction and
reported as fold enrichment (± SEM) and demonstrated increased binding of FOXO proteins to the RTK 50 UTRs upon AKT inhibition.
(D) BT-474 cells were treated as in (C) and collected for immunoblotting, demonstrating that knockdown of FOXO proteins associated with diminished induction
of the RTKs. See also Figure S5.
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AKT Inhibition Induces RTK Expression2.3-fold), whereas inhibition of FOXO protein expression with
siRNA abolished this effect. These data suggest that activation
of FOXO proteins is directly responsible for induction of RTK
transcription.
Combined Inhibition of AKT and HER1/2 Kinases
Is Effective In Vivo
The prevalence of AKT activation in human tumors has led to
a widespread effort to develop inhibitors of the pathway. Relief
of feedback inhibition of signaling by these inhibitors may limit
their therapeutic effects. The induction of HER3 expression in
response to the AKTi-1/2/3 in BT-474 cells is associated
with increased HER3 binding to PI3K and to HER2, as shown66 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.by co-immunoprecipitation and crosslinking experiments in
Figure S1.
We used HER kinase inhibitors to ask whether blocking induc-
tion of HER family kinase activity enhances the antitumor efficacy
of AKT inhibitors in vivo.We investigated the effects of the combi-
nation in two models in which AKT inhibition induces HER3:
BT474, in which HER2 is amplified (Figure 7A), and H292 non-
small cell lung cancer, in whichwild-type EGFR is overexpressed
(Figure 7B). In both models, AKT inhibition induces HER3 and
IGF1R/IR phosphorylation (Figures 7C and 7D).
In the BT474model, chronic administration of the AKT inhibitor
completely inhibits tumor growth but does not cause regression
(Figure 7A). In H292 the AKT inhibitor causes amarginal decrease
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Figure 7. HER1/2 Kinase Inhibition Improves Antitumor Efficacy When Given in Combination with the AKTi
(A) Mice bearing BT-474 tumors were randomized to (1) no treatment, (2) lapatinib 150 mg/kg three times/week, (3) AKTi-1/2 100 mg/kg three times/week, or (4)
combination of (2) and (3) and tumor size measured two times/week with the combination treatment demonstrating superior antitumor efficacy compared to the
single agents.
(B) Mice bearing NCI-H292 tumors were randomized to (1) no treatment, (2) gefitinib (Iressa) 150 mg/kg three times/week, (3) AKTi-1/2/3 100 mg/kg three times/
week, or (4) combination of (2) and (3) and tumor size measured by vernier calipers two times/week with the combination treatment demonstrating superior anti-
tumor effects to the single agents. The results in (A) and (B) are presented as the mean tumor volume ± SEM (n = 5 mice/group).
(C) Mice (n = 12) bearing BT-474 tumors were randomized to no treatment, treatment with a single dose of lapatinib 150 mg/kg, AKTi-1/2/3 100 mg/kg, or the
combination and collected at 6 and 12 hr posttreatment. Immunoblotting of tumor lysates demonstrates that AKT inhibition induces P-HER3 and P-IGF-1R/
INSR in vivo, and this is attenuated by lapatinib coadministration. Note, two mice treated for the 12 hr time points lacked adequate tumor tissue at retrieval
and were omitted.
(D) Mice bearing NCI-H292 tumors were treated with a single dose of gefitinib 150 mg/kg, AKTi-1/2/3 100 mg/kg, or the combination and collected at 6 and 12 hr
posttreatment. Immunoblotting of lysates demonstrates that AKT inhibition induces P-HER3 and P-IGF-1R/INSR, and this is attenuated by gefitinib coadminis-
tration. See also Figure S6.
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of feedback induction of HER kinases increases the therapeutic
effects of the AKT inhibitor, we used low doses of HER kinase
inhibitors that affect baseline HER3 phosphorylation only
minimally but do prevent induction of HER3/IGF1R/IR phosphor-
ylation in response to the AKT inhibitor (Figures 7C and 7D).
Although lapatinib given at a more frequent schedule has signifi-
cant antitumor effects in this model, at this schedule the lapatinib
had little effect. However, it significantly altered the response to
the AKT inhibitor, and the combination caused partial tumor
regression. Maximal doses of the AKT inhibitor alone cause
growth arrest without regression in this model.In the H292 model the AKT inhibitor did not significantly
block tumor growth. However, the addition of the EGFR kinase
inhibitor to the AKTi-1/2/3 caused significant and persistent
tumor regression (Figure 7B). Iressa by itself did significantly
inhibit tumor growth, but as previously reported, the effects
were transient and significantly less than the combination
(Buck et al., 2008). Thus, doses of HER kinase inhibitor sufficient
to prevent relief of feedback inhibition of HER3 by the AKT inhib-
itor sensitize tumors to this drug. In keeping with these data, we
find that prevention of RTK induction with an Hsp90 inhibitor also
sensitizes tumors to AKT inhibitors and causes profound tumor
regression in the BT474 model (Figure S6).Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc. 67
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It is increasingly clear that dysregulation of mitogenic signaling
by constitutively activated oncoproteins in cancer cells drives
high levels of feedback inhibition of the signaling network (Cour-
tois-Cox et al., 2006; O’Reilly et al., 2006; Pratilas et al., 2009).
This may have important phenotypic consequences in the trans-
formed cell. Hyperactivation of signaling by the oncoprotein may
depend on its relative insensitivity to negative feedback or to
other mutations that inactivate elements of the feedback
machinery. Anticancer drugs that inhibit oncoprotein function
will relieve this negative feedback and, thus, reactivate multiple
signaling pathways that limit the extent and duration of the
anticancer effects.
The PI3K-AKT signaling pathway is a central downstream
effector of growth factor receptors and is often dysregulated in
cancer. The insulin and IGF-1Rs exert many of their physiologic
effects by activating PI3K, but mutation or overexpression of
other receptors, such as HER2 in breast cancer, commonly
dysregulates the pathway in tumors (Holbro et al., 2003; Kooij-
man et al., 1995). Activation of PI3K-AKT leads to activation of
many downstream targets that together account for the prolifer-
ative, antiapoptotic, and metabolic effects of the pathway. Of
these, the mTOR kinase has attracted much attention because
of its central function in integrating nutrient and energy avail-
ability and growth signals in the regulation of cell proliferation
and size. mTOR functions in two multiprotein complexes,
mTORC1 andmTORC2 (Guertin and Sabatini, 2007). The natural
product rapamycin is a specific inhibitor of mTORC1 and leads
to dephosphorylation of its two most well-characterized
substrates, S6 kinase and 4EBP1 (Brunn et al., 1997; von Man-
teuffel et al., 1997). It thereby inhibits cap-dependent translation
and cell proliferation.
Experiments with rapamycin first revealed the extent and
clinical implications of oncogene-induced feedback. Insulin
signaling is feedback regulated in part by an mTOR/S6K-depen-
dent phosphorylation and downregulation of the major IR
substrate IRS1 (Haruta et al., 2000). Inhibition of mTOR with
rapamycin relieves this feedback, activates insulin and IGF
signaling, and thereby activates PI3K and ERK signaling (O’Reilly
et al., 2006). This occurs in vivo in patients and likely decreases
the therapeutic efficacy of the drug (Mellinghoff et al., 2005;
O’Reilly et al., 2006).
PI3K and AKT regulate many processes besides mTORC1
activity. We reasoned that in tumor cells, mutational activation
of the PI3K-AKT pathway would induce mTOR-independent
feedback pathway as well. We used a selective, allosteric inhib-
itor of AKT to assess AKT-dependent feedback in breast tumor
cells in which the pathway is driven by amplification of HER2.
We found that inhibition of AKT in these cells induced the expres-
sion of HER3. There was a concomitant induction of HER3-HER2
heterodimers and a marked induction of HER3 phosphorylation.
The results are consistent with the idea that AKT activation
causes feedback inhibition of HER kinase expression, especially
of HER3, which when phosphorylated, docks with and activates
PI3K. The induction of HER3 in response to AKT inhibition is
associated with an increase in HER2-HER3 heterodimers and
leads to increased HER3 phosphorylation. HER3 phosphoryla-
tion is blocked by the HER1/2 kinase inhibitor lapatinib, but the68 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.increase in HER3 expression is not. This finding suggests that
the increase in HER3 expression is in large part responsible for
the observed increase in phosphorylation.
HER3 expression is induced by inhibitors of PI3K or AKT or by
knockdown of AKT. That induction of HER3 expression and
phosphorylation in response to AKT inhibition represents release
of AKT-dependent feedback inhibition of the pathway is sup-
ported by the downregulation of HER3 expression that occurs
when the AKT inhibitor is washed out of cells. We used phos-
pho-RTK arrays to ask whether AKT-induced negative feedback
was confined to HER3 or involved other receptors as well. We
found that, although HER3 induction was very prominent, the
phosphorylation of multiple other receptors was induced as
well. Induction of receptor phosphorylation was not confined
to HER2-dependent breast cancers; it occurred in tumor cells
derived from all lineages tested (breast, prostate, ovary, lung,
melanoma). We identified a set of nine RTKs whose phosphory-
lation is commonly induced after AKT inhibition. Four of these
(HER3, IGF1R, IR, and EphA7) responded in almost all cells
tested.
Phosphorylated HER3 has a high capacity and affinity for
PI3K, docking it to the membrane. Themost obvious physiologic
role of PI3K-AKT signaling is mediating the effects of the insulin
and IGF-1Rs. It seems from our data that these three receptors
are coordinately feedback downregulated by AKT when the
pathway is activated. AKT inhibition induces the expression as
well as the phosphorylation of HER3, IGF1R, and IRs. Induction
of other kinases such as RET and HER4 is confined to phosphor-
ylation; expression is typically unaffected. HER2 is the dominant
activated kinase in breast cancers in which it is amplified, and in
these tumors the induction of phosphorylation of the other RTKs
is HER2 dependent. Lapatinib blocks their phosphorylation, but
not the induction of expression of IGF1R and IR. Previous work
by other labs has demonstrated that IGF1R and IR kinases are
not antagonized by lapatinib at doses as high as 3 mM, and the
lack of effect of lapatinib upon IGF1R and IR in non-HER2 driven
models like H1975 (Figure S3) supports that the activity seen
here is not due to direct inhibition of those kinases. Whether
the HER-kinase dependence of induction of IGF-1R/IR phos-
phorylation represents transphosphorylation of these kinases
by HER2 or a HER2-dependent activation of autophosphoryla-
tion is under investigation. Activation of IGF1-R and IR by AKT
inhibition does involve both induction of expression and HER
kinase-dependent phosphorylation of these kinases. In the
non-small cell lung cancer model H292, the induction of phos-
phorylation of some RTKs like HER3 is HER kinase inhibitor
sensitive. Others, such as FGFR and IGF1R, are insensitive. It
is clear that activation of AKT in tumors induces a complex and
broad pattern of feedback inhibition of RTKs that is relieved by
inhibition of AKT.
TORC1 inhibition by rapamycin has also been shown to acti-
vate signaling, and less-selective PI3K inhibitors that target
both mTORC1 and PI3K have been shown to induce HER3
expression (Amin et al., 2010; Sergina et al., 2007). We asked
whether AKT inhibition activated signaling via inhibition of
mTORC1. Rapamycin partially reproduced the effects of AKT
inhibition, inducing the phosphorylation of HER3 along with
several other RTKs. However, induction of HER3 was consider-
ably weaker than that observed with AKT inhibition, and the
Figure 8. AKT Inhibition and mTORC1 Inhibition Relieve Feedback Inhibition at Unique Nodes of Oncogenic Growth Factor Signaling Path-
ways
Depicted in middle panel is the steady-state feedback program elicited by activation of AKT and/or mTORC1. Receptor activation stimulates PI3K-AKT activity,
which inhibits FOXO-mediated activation of RTK transcription. Receptor stimulation also activates mTORC1, which directs inhibitory feedback upon the expres-
sion of IRS-1, thereby attenuating PI3K-AKT activity. In the left panel, rapamycin blocksmTORC1 action, relieving the feedback inhibition upon IRS-1 and causing
hyperactivation of PI3K-AKT signaling. In the right panel, AKT inhibition blocks both AKT and the downstreammTORC1. The consequence is to relieve mTORC1
feedback but also to activate FOXO-driven transcription of RTKs and stimulate PI3K-AKT activity through higher RTK expression and activity.
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was unaffected by rapamycin. The differences between the
effects of the AKT inhibitor and rapamycin suggest that there
are AKT-regulated feedback pathways that are not mediated
by TORC1.
A clue to the nature of these pathways came from studies on
the mechanism of induction of expression of HER3, IGF1R,
and IR. AKT inhibition results in marked induction of the mRNAs
encoding these receptors, whereas rapamycin has either no or
marginal effects. AKT has been shown to phosphorylate the
FOXO family of transcription factors and thereby prevent their
nuclear translocation, thus inhibiting their function (Brunet
et al., 1999). We show that AKT inhibition recruits FOXO proteins
to the HER3 promoter and that FOXO1/3/4 knockdown with
siRNA suppresses the induction of IGF1-R/IR/HER3 expression
and phosphorylation. We note that the knockdown of FOXO
proteins has little effect on the basal expression of the RTKs.
We postulate that in these cells with activated PI3K/AKT
signaling, FOXOs are effectively inhibited, and expression of
HER3, IGF1R, and IR is dependent on other factors in this state.
However, AKT inhibition results in activation of these transcrip-
tion factors, enabling them to promote RTK expression. Thus,
we conclude that AKT regulates the expression of these recep-
tors by inhibiting FOXO-dependent transcription.
We propose the following model based on our current under-
standing to explain the regulation of PI3K-AKT signaling by
negative feedback in tumors and how it is affected by targeted
drugs (Figure 8). Receptor activation of PI3K-AKT causes
AKT-dependent phosphorylation of FOXO proteins, which
downregulate the expression of some of the receptors that are
tightly coupled to PI3K, including HER3, IGF1R, and IR. In
addition, AKT activation leads to activation of TORC1 and S6K,
which feedback inhibits IRS1 expression and other undefined
regulators of receptor signaling. The result is down modulation
of the signal.Therapeutic inhibition of different components of the pathway
reactivates feedback, but by mechanisms specific to the in-
hibited target (Figure 8). Thus, AKT inhibition will result in
activation of FOXO-dependent transcription of receptors and
inhibition of S6K-dependent inhibition of signaling with resultant
activation of multiple receptors. The downstream effects of AKT
will be suppressed, but other RTK-driven signaling pathways will
be activated. In contrast, TORC1 inhibition blocks S6K-depen-
dent feedback, activates IGF and HER kinases, but not their
expression, and, thus, activates both AKT and ERK signaling.
These findings have important basic and therapeutic implica-
tions. The enhancement of signaling by autocrine activation or
mutation of RTKs that activate PI3K-AKT signaling would be
expected to be limited by negative feedback. Selection of onco-
genes that encode proteins that overcome or are unresponsive
to feedback would be favored (e.g., activating mutation in PI3K
or loss of PTEN). All drugs that inhibit components of dysregu-
latedmitogenic signaling pathways would be expected to relieve
feedback inhibition of other components of the signaling
network. This may reduce the antitumor effects of the drug but
also ameliorate toxicity. Combined inhibition of the oncoprotein
and key pathways reactivated by inhibition of negative feedback
should have enhanced antitumor activity. This is consistent with
our finding that the AKT inhibitor causes tumor regressions when
combined with low doses of HER kinase or HSP90 inhibitors
that prevent or attenuate induction of receptor phosphorylation.
Whether effective inhibition of both PI3K-AKT signaling and
feedback reactivated pathways will have an enhanced thera-
peutic index will have to be evaluated in clinical trials.EXPERIMENTAL PROCEDURES
Reagents
AKTi-1/2 and AKTi-1/2/3 (MK-2206) were from Merck; both drugs were dis-
solved in DMSO for in vitro studies. For in vivo studies, AKTi-1/2 was dissolvedCancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc. 69
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ously, whereas AKTi-1/2/3 was dissolved in 30% Capitisol and administered
by oral gavage. A detailed list of other reagents utilized is provided in
Supplemental Experimental Procedures.
Immunoblotting
Lysates from cells in culture were prepared by washing twice in cold PBS
followed by lysis with either SDS-lysis buffer (50 mM Tris-HCl [pH 7.4], 2%
SDS) or RIPA-lysis buffer supplemented with protease and phosphatase
inhibitors (Pierce Chemical). For immunoprecipitations, cells were lysed with
NP40-lysis buffer (50 mmol/l Tris [pH 7.4], 1% NP40, 150 mmol/l NaCl,
40 mmol/l NaF) supplemented with protease and phosphatase inhibitors
(Pierce Chemical). For lysis in SDS, lysates were boiled for 5 min followed by
brief sonication. Lysates were cleared by centrifugation at 14,000 3 g
(10 min), and the supernatant was collected. Protein concentration of each
sample was determined using the BCA kit (Pierce) per manufacturer’s instruc-
tions. Twenty-five or 50 mg protein was loaded onto 6% or 10% SDS-PAGE
minigels for immunoblotting. Further details on immunoprecipitation and
crosslinking are provided in Supplemental Experimental Procedures.
RT-PCR
TaqMan reactions were done using an ABI 7500 real-time quantitative PCR
system. For data analysis, raw counts were normalized to housekeeping
gene average for the same time point and condition (DCt). Counts are reported
as fold change relative to the untreated control (2DDCt). A list of probes and
reagents used is provided in the Supplemental Experimental Procedures.
ChIP Assays
ChIP assays were performed according to the manufacturer’s instructions
(MagnaChIP assay kit; Upstate Biotechnology). Approximately 1 3 107 cells
were used for each immunoprecipitation. DNA was amplified by PCR using
primer pairs against the HER3 50 UTR [GPH003183(-)01A from SA
Biosciences], IGF-1R 50 UTR [GPH004604(-)02A)] and IR 50 UTR
[GPH019975(-)01A] and SYBR Green reaction mix (SA Biosciences), and
product was quantified using an ABI 7500 real-time quantitative PCR system.
Reactions were performed in triplicate, and the mean was normalized to input
chromatin and reported as relative fold enrichment ± SEM.
Cell Lines
BT-474, SKBr-3, MDA-MB-453, MDA-MB-361, LNCAP, NCI-H292, MDA-MB-
231, HCC-1806, NCI-H441, MCF10A, UACC-893, and NCI-H1975 were
obtained from the American Type Culture Collection. H3255 cells were a gift
from B. Johnson and P. Janne (Dana Farber Cancer Institute), and IGROV-1
cells were a gift from D. Spriggs (Memorial Sloan-Kettering Cancer Center).
Details on medium conditions and use of cell lines in xenograft studies are
found in Supplemental Experimental Procedures.
Animal Studies
Four to six-week-old nu/nu athymic BALB/c female mice were obtained from
the NCI-Frederick Cancer Center and maintained in pressurized ventilated
caging. All studies were performed in compliance with institutional guidelines
under an IACUC approved protocol (Memorial Sloan-Kettering Cancer Center
No. 09-05-009). For efficacy studies, mice with well-established tumors
were selected and randomized approximately 14 days postimplantation
(size >200 mm3); BT-474 xenograft tumors were established in nude mice by
subcutaneously implanting 0.72 mg sustained release 17b-estradiol pellets
with a 10 g trocar into one flank followed by injecting 13 107 cells suspended
1:1 (volume) with reconstituted basement membrane (Matrigel, Collaborative
Research) on the opposite side 3 days afterward. Mice were treated with
AKTi-1/2, AKTi-1/2/3, gefitinib, SNX5422, or lapatinib with the indicated
doses. Tumor dimensions were measured with vernier calipers and tumor
volumes calculated: p/6 3 larger diameter 3 (smaller diameter)2.
RTK Arrays
Human Phospho-RTK arrays were utilized according to manufacturer’s
instructions. Briefly, cells were washed with cold PBS and lysed in NP40 lysis
buffer, and 50–250 mg of lysates was incubated with blocked membranes
overnight. Membraneswere subsequently washed and exposed to chemilumi-70 Cancer Cell 19, 58–71, January 18, 2011 ª2011 Elsevier Inc.nescent reagent and exposed to X-ray film. Quantification of pixels was per-
formed by densitometry using Adobe CS2 and Fuji Film Multi Gauge software.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:10.
1016/j.ccr.2010.10.031.
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